ClinicalTrials.gg
Not yet recruitingNCT07345390Updated Jan 15, 2026

Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris

A Phase 2 interventional study of KR230109 cream 0.025% and KR230109 cream 0.05% in Acne Vulgaris, sponsored by Jiangxi Kvvit Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Jiangxi Kvvit Pharmaceutical Co., Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This study will evaluate the safety, efficacy and pharmacokinetics of KR230109 cream compared with placebo in Patients (18-40 Years) with Acne vulgaris

02

Conditions studied

  • Acne Vulgaris

Browse trials for

03

In context

Acne Vulgaris

792 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

This study's planned enrollment of 180 is above the median of 70 across 674 interventional studies indexed under Acne Vulgaris.

Browse Acne Vulgaris studies →

Lead sponsor

Jiangxi Kvvit Pharmaceutical Co., Ltd. is the lead sponsor of 7 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 40 years old (as of the time of signing the form), regardless of gender;
  2. Patients clinically diagnosed with mild to moderate facial acne vulgaris (refer to the "Chinese Acne Treatment Guidelines" 2019 revised edition), and with an overall facial IGA (Investigator Global Assessment) score of 2 to 3 by the study doctor;
  3. Baseline requirements: For patients with mild to moderate acne, the count of facial inflammatory lesions (papules and/or pustules) should be >=10 and \<=40; the count of non-inflammatory lesions (open and/or closed comedones) should be >=20 and \<=60; no facial nodules should exist;
  4. Participants must be willing to use only non-acne-treating skin care products during the trial and comply with the precautions required by the protocol;
  5. Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the written informed consent form, and be able to complete the entire trial process as required;
  6. From the time of signing the informed consent form to 3 months after the last administration, female participants of childbearing age or male participants whose partners are of childbearing age must agree and be able to take effective measures, such as avoiding sexual activity or using reliable contraceptive methods like condoms or intrauterine devices.

Exclusion criteria

Exclusion Criteria:

  1. Those known to be allergic to KR230109 or drugs with the same mechanism of action such as tazarotene, adapalene, or any of their components;
  2. Those with a history of any serious clinical systemic diseases or surgeries, such as diseases of the circulatory system, nervous system, hematological system, immune system, or mental system;
  3. Those with concurrent other obvious skin diseases at the affected area that may affect the clinical evaluation of the researchers or require concurrent treatment, such as solar dermatitis, psoriasis, seborrheic dermatitis, rosacea, eczema, severe acne, and extremely severe acne (such as conglobate acne, fulminant acne, etc.);
  4. Those with secondary acne, such as occupational acne and acne caused by ;
  5. Those with facial skin or hair conditions that may interfere with clinical assessment (such as significant beards, sideburns, or mustaches);
  6. Those who plan to use any adjunctive therapies or concomitant treatments for acne during the trial;
  7. Those who have used acne-specific functional skin care products within one week before the start of treatment;
  8. Those who have used topical retinoids, antibiotics, corticosteroids, or other topical acne treatments on the face within two weeks before the trial;
  9. Those who have taken oral retinoids, antibiotics, corticosteroids (including intramuscular or intralesional injections, except for stable use of inhaled, intranasal, or intraocular corticosteroids for the treatment of underlying diseases and without impact on acne treatment), spironolactone, or other acne medications within four weeks before the trial;
  10. Those who have undergone physical or chemical acne treatments within four weeks before the trial;
  11. Those who have participated in other clinical trials and used trial drugs or medical devices within 90 days before screening or plan to participate in other clinical trials during the trial;
  12. Those whose vital signs, physical examinations, laboratory tests (blood routine, urine routine, blood biochemistry), , etc., are abnormal and have clinical significance as assessed by the researchers and may affect the evaluation of this trial;
  13. Those who are positive for surface antigen, antibody, syphilis-specific antibody, or antibody;
  14. Pregnant or lactating women or those with positive blood or urine pregnancy tests;
  15. Those who need prolonged or excessive exposure to sunlight, such as sunbathing;
  16. Those with a history of alcohol abuse or drug abuse;
  17. Those who, in the opinion of the researchers, have poor compliance, or have conditions that may interfere with the study outcome, or those who, in the opinion of the researchers, have any other conditions that make them unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    KR230109 cream 0.025%

    Participants applied KR230109 cream once daily for 12 consecutive weeks.

    Drug: KR230109 cream 0.025%

  • Experimental
    KR230109 cream 0.05%

    Participants applied KR230109 cream once daily for 12 consecutive weeks.

    Drug: KR230109 cream 0.05%

  • Placebo comparator
    placebo

    Participants applied placebo once daily for 12 consecutive weeks.

    Drug: Placebo

Interventions

  • DrugKR230109 cream 0.025%

    KR230109 cream 0.025% is indicated for the topical treatment of acne vulgaris in patients

  • DrugKR230109 cream 0.05%

    KR230109 cream 0.05% is indicated for the topical treatment of acne vulgaris in patients

  • DrugPlacebo

    Vehicle cream manufactured to mimic look and feel of KR230109 Cream but without the active ingredient.

    Also known as: Vehicle cream

06

What researchers measure

Primary outcomes

  1. The percentage change from baseline in the count of non-inflammatory facial lesions

    The percentage change from baseline in the count of non-inflammatory facial lesions at Week 12 compared with placebo in each treatment group.

    Time frame: week 12

  2. The percentage change from baseline in the count of inflammatory facial lesions

    The percentage change from baseline in the count of inflammatory facial lesions at Week 12 compared with placebo in each treatment group.

    Time frame: week 12

Secondary outcomes

  1. The average percentage change from baseline in the counts of inflammatory and non-inflammatory skin lesions

    The average percentage change from baseline in the counts of inflammatory and non-inflammatory skin lesions at weeks 2, 4, 8 of treatment compared with placebo for each treatment group.

    Time frame: week 2,4,8

  2. The absolute change from baseline in the counts of inflammatory and non-inflammatory skin lesions

    The absolute change from baseline in the counts of inflammatory and non-inflammatory skin lesions at weeks 2, 4, 8, 12 of treatment compared with placebo for each treatment group.

    Time frame: week 2,4,8,12

  3. The average percentage change and absolute change from baseline in the total skin lesion count

    The average percentage change and absolute change from baseline in the total skin lesion count at weeks 2, 4, 8, 12 of treatment compared with placebo for each treatment group.

    Time frame: week 2,4,8,12

  4. The proportion of participants in each treatment group with at least a 2-point reduction in IGA score from baseline and an IGA score of 0 or 1

    The proportion of participants in each treatment group with at least a 2-point reduction in IGA score from baseline and an IGA score of 0 or 1 at weeks 2, 4, 8, 12 of treatment compared with placebo.

    Time frame: week 2,4,8,12

  5. Safety endpoints

    Adverse events (AEs), local skin reactions (LSRs), physical examinations, vital signs, electrocardiograms (ECGs), and abnormal clinical laboratory tests (blood routine, blood biochemistry, urine routine).

    Time frame: from day 1 to week 12

  6. Steady-state PK parameters of KR230109: Cmax,ss.

    Steady-state PK parameters of KR230109: Cmax,ss.

    Time frame: week 4

  7. Steady-state PK parameters of KR230109: AUC0-24h,ss, etc.

    Steady-state PK parameters of KR230109: AUC0-24h,ss, etc.

    Time frame: weeks 4

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Oct 2026, 9 months later.

Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's planned 9 months is close to that.

Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2025
First posted
Jan 15, 2026
StartEst.
Jan 10, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07345390
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Jan 10, 2026 (estimated)
Primary completion
Oct 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Jan 15, 2026

Study contacts

jianzhong zhang, Master
Contact
rmpkzc@163.com
+86 18001315877
cheng zhou, Doctor
Contact
rmzjz@126.com
+86 18910291182

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion